



## *Escherichia coli* – Sepsis (peritonitis)

### Procedure Summary

- Immunocompetent CD-1 mice, eight weeks old females
- *Escherichia coli* (ATCC 25922)
- Bacterial challenge by intraperitoneal route
- Mucin 5%
- Reference compound: Ciprofloxacin (IP); Test molecule (IP)

### Experimental readouts

- Survival rate
- Weight loss
- Clinical score

### Optional Services

- CFU determination (peritoneal fluid, spleen...)
- Cytokine and chemokine analysis
- Pharmacokinetics

### Literature / reference

- Papareddy *et al.*, Plos pathogens. 2010. «The TFPI-2 Derived Peptide EDC34 Improves Outcome of Gram-Negative Sepsis”.
- Internal data


### Animal Welfare

- Each experimental protocol is approved by the local ethics committee for animal experimentation of Grand Campus Dijon (Burgundy, France) and performed in accordance to the current recommendations of the European Institute of Health EU Directive 86/609

### Facilities

- These assays are performed at our BSL2 laboratory / zootechnical center in Dijon, France

Efficacy of test molecule at 2 different concentrations compared to ciprofloxacin on survival rate in a murine model of septicaemia induced by *Escherichia coli*.



Our scientific team will readily accommodate client-specific alterations and will provide expert advice and guidance for your efficacy studies

For more information please contact : [info@vivexia.fr](mailto:info@vivexia.fr)